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ABSTRACT
Neutrophils play an important role in the lung tumour 
microenvironment. We hypothesised that radiolabelled 
neutrophils coupled to single- photon emission CT 
(SPECT) may non- invasively quantify neutrophil uptake 
in tumours from patients with non- small cell lung cancer. 
We demonstrated increased uptake of radiolabelled 
neutrophils from the blood into tumours compared 
with non- specific uptake using radiolabelled transferrin. 
Moreover, indium-111- neutrophil activity in the tumour 
biopsies also correlated with myeloperoxidase (MPO)- 
positive neutrophils. Our data support the utility of 
imaging with In-111- labelled neutrophils and SPECT- CT 
to quantify neutrophil uptake in lung cancer.
INTRODUCTION
Lung cancer is the leading cause of cancer- related death 
worldwide. Inflammation has emerged as a hallmark 
of tumourigenesis, contributing to the development 
and progression of a range of cancers. Neutrophils are 
known to be important players in the tumour micro-
environment and these tumour- associated neutrophils 
(TANs) are broadly classified into an N1 tumour- 
suppressing phenotype or an N2 tumour- promoting 
phenotype. While neutrophils may exert both pro- 
tumorous and antitumorous functions, the prevailing 
view is that they serve to exclude T cell access and 
hence promote tumour progression. In murine studies, 
Ly- 6G- specific depletion of neutrophils reduced the 
metastatic burden in the lungs,1 while in kras- driven 
mouse models of lung cancer, Gr1+ neutrophils 
were found to favour tumour growth, reduce T cell 
homing, and antagonise anti- programmed cell death 
protein 1 (PD-1) immunotherapy.2 Furthermore, 
neutrophil derived mediators have been shown to 
be pro- tumourigenic; neutrophil elastase contributes 
to tumour proliferation,3 MMP-9 increases vascular 
endothelial growth factor release (from the extracel-
lular matrix) to promote angiogenesis,4 and neutrophil 
extracellular traps can sequester circulating tumour 
cells in the pulmonary microvasculature, promoting 
the development of metastasis.5
Although evidence exists that infiltrating neutro-
phils accumulate in non- small cell lung cancer 
(NSCLC),6 direct non- invasive imaging and quan-
tification of neutrophils within patient tumours has 
never been described. Such quantification could aid 
in predicting the therapeutic response and clinical 
outcome of patients. Here we describe quantitative 
single- photon emission CT (SPECT)- CT using indium-
111- radiolabelled autologous neutrophils to quantify 
neutrophil uptake in tumours of patients with early 
stage lung cancer, using indium- labelled transferrin as 
a marker for non- specific uptake of non- cell- bound 
activity. We also correlated tissue concentrations of 
radiolabelled neutrophils with histological evidence 
of MPO+ neutrophils. These findings have important 
implications for the use of quantitative SPECT- CT to 
monitor the extent of neutrophil uptake by tumours.
CLINICAL CASES
Six patients were selected for entry into the study met 
the following criteria: (1) positron emission tomog-
raphy (PET) or biopsy confirmed preoperative stage 
I–II lung cancer in the mid- upper zones of the lung, 
(2) no prior chemotherapy or radiotherapy and (3) no 
other active malignancy. Biopsies were performed ≥1 
month prior to acquisition of SPECT images. Tumours 
in the mid- upper zones were chosen to avoid poten-
tial overlap of the signal with physiological uptake of 
radiolabelled cells in the liver. Patient characteristics 
can be found in online supplementary table 1 and the 
study protocol is summarised in online supplementary 
figure 1.
In four volunteers, neutrophils were isolated from 
peripheral venous blood using plasma- Percoll gradi-
ents and radiolabelled with indium-111- tropolonate, 
as described in online supplementary files. Given that 
increased vascularity of tumours could contribute 
to enhanced uptake of In-111- neutrophils,7 we also 
assessed the uptake of In-111- transferrin into tumours. 
Transferrin can be taken up by tumours non- specifically 
through highly permeable blood vessels. Hence, in two 
further patients, In-111- transferrin was prepared as a 
control for non- specific uptake (online supplementary 
files), so that specific focal accumulation of In-111- 
neutrophils in the tumour area can be compared.
Over 40 min of dynamic gamma camera imaging, 
labelled neutrophils displayed physiological kinetics 
in liver, lungs and spleen, in line with previous results 
from healthy volunteers (online supplementary figure 
2A).8 The recoveries of radiolabelled neutrophils 
from the peripheral blood 45 min after injection 
(online supplementary figure 2B) were comparable to 
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published data, indicating that the cells were not activated by isola-
tion and radiolabelling. As expected, In-111- transferrin behaved as a 
labelled plasma protein (online supplementary figure 2A,B).
SPECT- CT showed very clear and evident uptake of neutrophils 
into the tumour of a patient with squamous cell carcinoma (case 1; 
figure 1A–D). As shown in figure 1E, tumour uptake increased in 
patients with injected In-111- neutrophils with a median of 0.0038 
mL/min/mL (IQR; 0.0231–0.0531) compared with a median of 
0.0009 mL/min/mL for In-111- transferrin (IQR; 0.0004–0.0013). 
SPECT- CT with attenuation correction (figure 1F) showed an 
overall increase in In-111- neutrophil clearance into tumour with 
a median of 0.0103 mL/min/mL (IQR; 0.0021–0.0387) compared 
with a median of 0.0037 mL/min/mL for In-111- transferrin clear-
ance (IQR; 0.0008–0.0066). Of note, SPECT- CT without attenu-
ation correction increased In-111- neutrophil clearance compared 
with In-111- transferrin clearance in all four patients, but only in two 
patients following attenuation correction. Attenuation correction of 
SPECT images is known to improve quantitative accuracy of malig-
nant lesions in the body by reducing soft tissue artefacts.9 Therefore, 
we propose that the attenuation corrected values provide a more 
representative quantification of neutrophil clearance.
The median peripheral neutrophil count was higher in the In-111 
neutrophil patient group compared with the In-111 transferrin 
group (online supplementary table 1); however, the correlation 
coefficient between the neutrophil count and the non- attenuation 
corrected Patlak- Rutland slope (r=0.6, p=0.24) or the attenuation 
corrected Patlak- Rutland slope (r=0.20, p=0.71) was not significant 
for the six cases.
On cell counting of tissue ex vivo, case 1 displayed substan-
tial accumulation of neutrophils in the centre (median 21 MPO+ 
neutrophils per hpf (IQR; 14–35) and periphery (median 19 
MPO+ neutrophils per hpf (IQR; 15–29) of the tumour compared 
with the background parenchyma (median 5 MPO+ neutro-
phils per hpf (IQR; 4–11) (figure 1G,H). Similar findings were 
obtained in one further patient with a squamous cell carcinoma 
(online supplementary fig 3). There was no discernible neutrophil 
infiltration at the tumour centre or periphery in the patient with 
adenocarcinoma (online supplementary fig 3). When all four cases 
were combined, the radiolabelled neutrophil gamma counts posi-
tively correlated with the number of MPO+ neutrophils (figure 1I; 
r=0.50, 95% CI 0.291 to 0.666; p<0.0001). Of interest, neutro-
phils were detected by immunohistochemistry (IHC) when the 
gamma radiation counts were low, suggesting the presence of 
tissue resident neutrophils.
DISCUSSION
In the present study, we demonstrated quantitative in vivo 
SPECT- CT imaging of radiolabelled neutrophil uptake in 
tumours of patients with lung cancer. Our study also established 
that MPO+ neutrophils in lung resections correlated with radio-
labelled neutrophil counts. Such a non- invasive imaging strategy 
could have important implications for monitoring neutrophil 
Figure 1 Quantification of radiolabelled neutrophils and radiolabelled transferrin in lung tumours of patients with early stage lung cancer. SPECT- 
CT images showing (A) transaxial, (B) coronal with three- dimensional reconstruction of tumour, (C) sagittal and (D) coronal plane from a patient with 
squamous cell carcinoma (case 1). Images show accumulation in the tumour (outlined in green) and physiological uptake in the liver (L), spleen (S) 
and vertebra (V) 20 hours after reinjection of In-111- labelled neutrophils. (E) and (F) Quantification of tumour uptake of In-111- labelled neutrophils 
(cases 1–4) and In-111- labelled transferrin (cases A and B) using non- attenuation corrected (E) and attenuation corrected values (F). (G) Tissue 
gamma counts and MPO+ neutrophil counts from the background parenchyma, peri- tumorous parenchyma, tumour periphery and tumour centre 
of a subject with squamous cell carcinoma (case 1). (H) Background parenchyma and tumour centre cores from case 1 (upper panels) alongside 
representative myeloperoxidase (MPO) immunohistochemical staining (lower panels). Magnification ×400. (I) Correlation between gamma radiation 
counts and MPO+ neutrophil counts in four subjects. MPO+ neutrophils were counted in four high powered fields. Correlation coefficients were 
calculated using Spearman correlation analysis.
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infiltration into tumours, and assessing the impact of neutrophil- 
targeted therapies in NSCLC.
Two previous studies have reported enhanced uptake of 
In-111 mixed leukocytes and In-111 granulocytes into a 
number of localised malignant neoplasms such as pulmonary 
sarcoma, although without quantitative measurements and 
a subjective scoring protocol.10 11 There is current interest 
in quantifying tissue concentration of single- photon emit-
ting tracers using attenuation- corrected SPECT- CT, with 
the aim of bringing SPECT- CT in line with PET- CT; we 
believe ours is the first attempt to do so in cell trafficking 
studies. The importance of our approach lies in the ability 
to fully exploit techniques such as Patlak- Rutland analysis, 
which, as in PET- CT, rely on absolute tissue quantification. 
In our previous studies of neutrophil trafficking in lung 
tissue, we circumvented this by normalising the Patlak- 
Rutland slope to the intercept of the plot, which reflects 
distribution volume of tracer in the tissue (the margin-
ated pulmonary neutrophil pool). However, in solid tissue 
such as tumour, the quantitative nature of the intercept 
is uncertain. Quantitative SPECT- CT has general value in 
studies based on labelled neutrophils because quantifica-
tion of neutrophil accumulation in enclosed spaces, like 
abscesses (as opposed to open tracts), uses crude indices 
such as abscess/background ratios at arbitrarily selected 
time points post- injection.
Of interest, we observed inter- tumour heterogeneity with 
respect to neutrophil uptake into tumours by both imaging 
and immunohistochemistry approaches, consistent with 
previous immunohistochemistry studies. A larger scale study 
will be required to understand the prognostic implication 
of such variable neutrophil infiltration. Some authors have 
suggested that, in addition to neutrophil abundance, the 
specific location of neutrophils within the tumour has prog-
nostic relevance. Sody et al, using a murine model of neutro-
phil trafficking, found that neutrophils exhibit distinct 
migratory patterns depending on their localisation to intra- 
tumorous or peri- tumorous regions.12
Given the broadly pro- tumourigenic role of neutrophils, 
modulation of neutrophil migration into tumours is an attractive 
therapeutic approach in NSCLC. Indeed, targeting neutrophil 
recruitment may be beneficial as adjuvant therapy. The CXCR2 
pathway has a major role in the control of neutrophil recruit-
ment into tumours, and antagonists of the CXCR2 receptor have 
reduced tumour growth in murine studies. Phase II clinical trials 
using CXCR2 inhibitors in NSCLC patients are on- going.13 Our 
findings thus offer the prospect of imaging neutrophils in clinical 
trials to better understand the therapeutic response of targeting 
neutrophils.
Our study has several limitations. First, our results are drawn 
from a small sample size, and follow- up will be required to 
confirm the utility of neutrophil imaging in NSCLC. Second, 
as TANs exhibit significant heterogeneity, our study could 
not detect the maturity or activation status of the trafficked 
cells. Third, there are reports of increased transferrin receptor 
expression on lung cancer cells,14 which could limit the use of 
radiolabelled transferrin as a negative control. However, as 
both radiolabelled transferrin and radiolabelled neutrophils are 
injected in plasma, this will likely increase the baseline uptake 
in both cases.
In conclusion, we demonstrate how radiolabelled neutrophils 
and SPECT- CT can be combined to allow non- invasive quantifi-
cation of neutrophil accumulation in lung cancer. Further studies 
of in vivo neutrophil trafficking in NSCLC are warranted.
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